Legal and regulatory exposuremixed · 5 filings
“The Company was not subject to any material legal proceedings as of June 30, 2026 , and no material legal proceedings are currently pending or threatened.”10-Q · Aug 4, 2026 ↗
Tyra Biosciences, Inc.
TYRA
Market read
Tyra Biosciences, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Company-6.5% todayVolume comparison unavailable
Market group0 of 1 activeFGFR Precision Biotech · unavailable
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- TYRA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if TYRA's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- TYRA's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods0
Price observations328
Usable filing statements62
Verified relationships4
Evidence supporting the case
No qualifying supportive evidence was identified.
Evidence challenging the case
- Capital investment and capacity has repeated adverse evidence across 3 filings.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 11, 2026
22.016m-38.9%12m+84.8%24m—
What management says matters
Persistent and emerging business drivers
Capital investment and capacitynegative · 3 filings
“Investing Activities The increase of $143.4 million in net cash provided by investing activities for the nine months ended September 30, 2025, compared to the same period in 2024, was driven by a reduction in purchases of marketable securities of $133.4 milli…”10-Q · Nov 5, 2025 ↗
Macroeconomic conditionsmixed · 1 filings
“of our product candidates following approval, if any; • the cost and timing of manufacturing our product candidates; • significant and changing government regulation and regulatory guidance; • the ability to attract and retain personnel; • the impact of any b…”10-Q · Aug 14, 2025 ↗
Supply chain and availabilitymixed · 1 filings
“of our product candidates following approval, if any; • the cost and timing of manufacturing our product candidates; • significant and changing government regulation and regulatory guidance; • the ability to attract and retain personnel; • the impact of any b…”10-Q · Aug 14, 2025 ↗
Valuation discipline
Peer-relative valuation withheld
Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.
Scenario scaffold
Fewer than 4 annual revenue periods; too little history to scaffold scenarios.
Price action
How the market is pricing the story
22.01-6.5% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for TYRA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for TYRA. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind TYRA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
BBIOBridgeBio Pharma, Inc.competitorFeb 24, 2026 ▾
“Other companies are developing therapies for achondroplasia, including Ascendis Pharma A/S (TransCon CNP), Tyra Biosciences, Inc.”
Filing peers
No filing peers are available for this name yet.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
TYRA is currently a Leader in the organic co-movement group FGFR Precision Biotech. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for TYRA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.